SEAGEN INC. Seagen Inc. (Nasdaq:SGEN) today announced that new data for ADCETRIS® (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Data presentations will include updated safety and efficacy results from clinical trials examining the potential of ADCETRIS with novel combinations in patients with advanced stage classical Hodgkin lymphoma (HL), in patients with newly diagnosed CD30-expressing peripheral T-cell lymphoma (PTCL) and in patients with other histologies.
“We look forward to sharing new data for the continued development of ADCETRIS in combination with other therapies across patient populations,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Additionally, initial results will be presented from our SEA-BCMA program in patients with relapsed/refractory multiple myeloma.”
ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is approved in more than 75 countries for relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL).
Presentations of Company-Sponsored ADCETRIS Trials:
Abstract Title | Abstract # | Presentation | Lead Author |
The ECHELON-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
| #135 |
Oral presentation /
| S. Horwitz |
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens
| #1390 |
Poster presentation /
| S. Parsons |
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)—a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age
| #1966 |
Poster presentation /
| D. Flora |
Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma
| #1197 |
Poster presentation /
| D. Taft |
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary results from the single-arm phase 2 study (SGN35-027 Part B)
| #2454 |
Poster presentation /
| H. Lee |
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective
| #2440 |
Poster presentation /
| T. Phillips |
Classical Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma
| #2467 |
Poster presentation /
| A. Evens |
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the Echelon-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective
| #2466 |
Poster presentation /
| J. Burke |
SEA-BCMA, an investigational nonfucosylated monoclonal antibody: interim results of a phase 1 study in relapsed/refractory multiple myeloma patients (SGNBCMA-001) | #2740 |
Poster presentation /
| J. Hoffman |
Trials-In-Progress | |||
Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)
| #1369 |
Poster presentation /
| I. Flinn |
Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)
| #3564 |
Poster presentation /
| N. Bartlett |
Frontline Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin and Prednisone in Patients With Peripheral T Cell Lymphoma With Less Than 10% CD30 Expression (SGN35 032, Trial in Progress)
| #1401 |
Poster presentation /
| D. Jagadeesh |
Presentations of Investigator-Sponsored and Cooperative Group ADCETRIS Trials:
Abstract Title | Abstract # | Presentation | Lead Author |
Brentuximab vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas
| #133 |
Oral presentation /
| A. Herrera |
The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDTASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma
| #136 |
Oral presentation /
| D. Sibon |
Interim results of a multicenter pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukemia/lymphoma
| #1395 | Poster presentation /
Saturday, Dec. 11,
| C. Dittus |
Pacific: A Phase II Study of Brentuximab vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma
| #1408 |
Poster presentation /
| R. Steiner |
Brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP as salvage strategy for patients with primary refractory or relapsed classical Hodgkin’s Lymphoma. Preliminary results from the BRESELIBET prospective clinical
| #2459 |
Poster presentation /
| A. Sureda |
Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in 718 Patients with Relapsed/Refractory Hodgkin Lymphoma
| #879 |
Oral presentation /
| J. Driessen |
The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
| #81
|
Oral presentation /
| A. Lo |
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of Seagen’s products and product candidates, the company’s pipeline and the advancement of its research and development activities. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials, the possibility of adverse regulatory actions, and the potential for delays or setbacks in product development and the regulatory review process. More information about the risks and uncertainties faced by the company is contained under the caption “Risk Factors” included in Seagen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005817/en/
